Guard Therapeutics International (OM:GUARD) - Aktienkurs, Nachrichten und Analyse

GUARD Aktienübersicht

Guard Therapeutics International AB (publ), ein pharmazeutisches Unternehmen, identifiziert, entwickelt und vermarktet Therapien für die Diagnose und Behandlung von akuten Nierenschäden in Schweden.

Über das Unternehmen

GUARD grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	1/6
Künftiges Wachstum	1/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

Risikoanalyse

Erzielt weniger als 1 Million USD an Einnahmen (SEK0)

Die Erträge werden in den nächsten 3 Jahren voraussichtlich um durchschnittlich 13.5% pro Jahr sinken.

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Hat keine nennenswerte Marktkapitalisierung (SEK302M)

+ 1 mehr Risiko

Guard Therapeutics International AB (publ) Wettbewerber

Medivir

OM:MVIR

SEK 324.2m

Lipum

OM:LIPUM

SEK 311.8m

Alzinova

OM:ALZ

SEK 324.6m

Curasight

NGM:CURAS

DKK 236.8m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Guard Therapeutics International
Historische Aktienkurse
Aktueller Aktienkurs	SEK 25.20
52-Wochen-Hoch	SEK 46.00
52-Wochen-Tief	SEK 16.00
Beta	-0.077
11 Monat Veränderung	-6.67%
3 Monate Veränderung	-12.50%
1 Jahr Veränderung	-18.71%
33 Jahre Veränderung	-63.05%
5 Jahre Veränderung	-60.93%
Veränderung seit IPO	-99.73%

Aktuelle Nachrichten und Updates

Recent updates

Companies Like Guard Therapeutics International (STO:GUARD) Could Be Quite Risky

Apr 18

Guard Therapeutics International (STO:GUARD) Will Have To Spend Its Cash Wisely

Jan 04

Here's Why Guard Therapeutics International (STO:GUARD) Must Use Its Cash Wisely

Sep 20

Guard Therapeutics International (STO:GUARD) Is In A Good Position To Deliver On Growth Plans

Apr 06

We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Sep 09

Here's Why We're A Bit Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Feb 19

We're Not Very Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Aug 17

Companies Like Guard Therapeutics International (STO:GUARD) Are In A Position To Invest In Growth

Apr 19

Here's Why We're Watching Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Jan 04

Aktionärsrenditen

	GUARD	SE Biotechs	SE Markt
7D	3.3%	-2.3%	-1.9%
1Y	-18.7%	32.0%	21.8%

Rendite im Vergleich zur Industrie: GUARD unter dem Niveau der Branche Swedish Biotechs , die im vergangenen Jahr eine Rendite von 32% erzielte.

Rendite vs. Markt: GUARD hinter dem Markt Swedish zurück, der im vergangenen Jahr eine Rendite von 21.8 erzielte.

Preisvolatilität

Is GUARD's price volatile compared to industry and market?
GUARD volatility
GUARD Average Weekly Movement	6.9%
Biotechs Industry Average Movement	8.7%
Market Average Movement	5.4%
10% most volatile stocks in SE Market	10.9%
10% least volatile stocks in SE Market	3.2%

Stabiler Aktienkurs: GUARD hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: GUARDDie wöchentliche Volatilität (7%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2008	11	Tobias Agervald	guardtherapeutics.com

Guard Therapeutics International AB (publ), ein pharmazeutisches Unternehmen, identifiziert, entwickelt und vermarktet Therapien für die Diagnose und Behandlung akuter Nierenschäden in Schweden. Es bietet ROSGard an, einen biologischen Arzneimittelkandidaten, der Nierenschäden durch Schutz, Reinigung und Reparatur der betroffenen Zellen und Gewebe verhindert. Das Unternehmen war früher als A1M Pharma AB (publ) bekannt und änderte im Oktober 2019 seinen Namen in Guard Therapeutics International AB (publ).

Guard Therapeutics International AB (publ)'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Guard Therapeutics International im Vergleich zum Marktanteil des Unternehmens?
GUARD grundlegende Statistiken
Marktanteil	SEK 302.45m
Gewinn(TTM)	-SEK 78.82m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

-3.9x

Kurs-Gewinn-Verhältnis

Ist GUARD zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
GUARD Gewinn- und Verlustrechnung (TTM)
Einnahmen	SEK 0
Kosten der Einnahmen	SEK 0
Bruttogewinn	SEK 0
Sonstige Ausgaben	SEK 78.82m
Umsatz	-SEK 78.82m

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-6.41
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich GUARD auf lange Sicht entwickelt?

Historische Performance und Vergleiche

GUARD Aktienübersicht

Belohnungen

Risikoanalyse

Guard Therapeutics International AB (publ) Wettbewerber

OM:MVIR

SEK 324.2m

OM:LIPUM

SEK 311.8m

OM:ALZ

SEK 324.6m

NGM:CURAS

DKK 236.8m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Guard Therapeutics Announces First Patient in Europe Dosed in the Clinical Phase 2b POINTER Study

Guard Therapeutics International AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 7.185811 million.

First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER

New major risk - Financial position

Guard Therapeutics Receives Regulatory EU Approvals to Include Patients in its Phase 2b Study POInter

New minor risk - Shareholder dilution

Recent updates

Guard Therapeutics Announces First Patient in Europe Dosed in the Clinical Phase 2b POINTER Study

Guard Therapeutics International AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 7.185811 million.

First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER

New major risk - Financial position

Guard Therapeutics Receives Regulatory EU Approvals to Include Patients in its Phase 2b Study POInter

New minor risk - Shareholder dilution

New major risk - Share price stability

New major risk - Revenue and earnings growth

Companies Like Guard Therapeutics International (STO:GUARD) Could Be Quite Risky

No longer forecast to breakeven

New major risk - Share price stability

New major risk - Financial position

Guard Therapeutics International (STO:GUARD) Will Have To Spend Its Cash Wisely

New major risk - Revenue and earnings growth

Guard Therapeutics Reports Robust Efficacy of RMC-035 in Phase 2 (Akita) and Advances Clinical Development Program

Here's Why Guard Therapeutics International (STO:GUARD) Must Use Its Cash Wisely

New minor risk - Financial position

New major risk - Revenue and earnings growth

Guard Therapeutics International AB Announces Completion of Clinical Phase 2 Study AKITA

Guard Therapeutics Announces the Full Results from the Phase 1B Clinical Study of the Investigational Drug RMC-035 in Patients Undergoing Kidney Transplantation

Price target decreased by 36% to kr1.61

No longer forecast to breakeven

Price target decreased by 36% to kr1.61

Guard Therapeutics International (STO:GUARD) Is In A Good Position To Deliver On Growth Plans

No longer forecast to breakeven

Guard Therapeutics Announces First Patient in US Dosed with Study Drug in the Ongoing Global Phase 2 Clinical Trial AKITA

Guard Therapeutics International AB (Publ) Announces 134 of the Planned 268 Patients Have Been Dosed in the Global Randomized, Double-Blinded and Placebo-Controlled Phase 2 Clinical Trial

No longer forecast to breakeven

Guard Therapeutics International AB (publ) Receives FDA Fast Track Designation for RMC-035

Guard Therapeutics International AB (publ) Receives IND Approval from the FDA for RMC-035

We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Guard Therapeutics Announces That the First Patient Has Been Dosed in A Phase 1b Clinical Trial of the Investigational Drug RMC-035 (ROSgard) in Kidney Transplantation

Guard Therapeutics Announces That the First Patient Has Been Dosed in A Phase 1b Clinical Trial of the Investigational Drug RMC-035 (ROSgard) in Kidney Transplantation

Guard Therapeutics Receives Approval from the Swedish Medical Products Agency to Conduct A Clinical Study of RMC-035 in Kidney Transplantation

Price target decreased to kr2.15

High number of new and inexperienced directors

Guard Therapeutics International AB (publ) Appoints Torbjörn Larsson as Head of CMC (Chemistry, Manufacturing and Controls), Effective 1 May 2022

Guard Therapeutics International AB (publ) Provides In-Depth Information on Phase 2 Clinical Trial

Guard Therapeutics Announces First Patient Has Been Dosed in Guard Therapeutics' Phase 2 Clinical Trial of ROSgard

Forecast to breakeven in 2024

Here's Why We're A Bit Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Chief Executive Officer recently bought kr1.6m worth of stock

Guard Therapeutics Receives Approval to Expand the Global Phase 2 Study of Rosgard to Canada

Guard Therapeutics’ Application to Conduct a Phase 2 Clinical Trial of ROSgard is Approved by the German Medicines Regulator

Chief Executive Officer recently bought kr300k worth of stock

Guard Therapeutics International AB (Publ) Reports Positive Results from Preclinical Studies

We're Not Very Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Companies Like Guard Therapeutics International (STO:GUARD) Are In A Position To Invest In Growth

Guard Therapeutics appoints Sara Thuresson as Head of Clinical Operations

New 90-day high: kr1.50

Here's Why We're Watching Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Guard Therapeutics International AB (Publ) Completes Pre-IND meeting with FDA

Guard Therapeutics Appoints Ann-Kristin Myde as Head of Global Project Management, Effective 1 April 2021

New 90-day low: kr1.22

New 90-day low: kr1.23

Guard Therapeutics Reports Positive Top-Line Results from Phase 1 Study of Rosgard in Individuals with Renal Impairment

New 90-day high - kr1.60

Aktionärsrenditen

Preisvolatilität

Erträge & Einnahmen